Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 333

1.

New Fissure-attached Nodules in Lung Cancer Screening: A Brief Report from The NELSON Study.

Han D, Heuvelmans MA, van der Aalst CM, van Smoorenburg LH, Dorrius MD, Rook M, Nackaerts K, Walter JE, Groen HJM, Vliegenthart R, de Koning HJ, Oudkerke M.

J Thorac Oncol. 2019 Oct 10. pii: S1556-0864(19)33521-X. doi: 10.1016/j.jtho.2019.09.193. [Epub ahead of print]

PMID:
31606605
2.

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations.

Holleman MS, Al MJ, Zaim R, Groen HJM, Uyl-de Groot CA.

Eur J Health Econ. 2019 Sep 20. doi: 10.1007/s10198-019-01117-3. [Epub ahead of print]

PMID:
31541309
3.

Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.

Groen HJM, van der Heijden EHFM, Klinkenberg TJ, Biesma B, Aerts J, Verhagen A, Kloosterziel C, Pieterman R, van den Borne B, Smit HJM, Hoekstra O, Schramel FMNH, van der Noort V, van Tinteren H, Smit EF, Dingemans AC; NVALT Study Group, the Netherlands.

Br J Cancer. 2019 Aug;121(5):372-377. doi: 10.1038/s41416-019-0533-3. Epub 2019 Jul 24.

PMID:
31337877
4.

Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors.

Tamminga M, de Wit S, Hiltermann TJN, Timens W, Schuuring E, Terstappen LWMM, Groen HJM.

J Immunother Cancer. 2019 Jul 10;7(1):173. doi: 10.1186/s40425-019-0649-2.

5.

Factors determining the effect of prophylactic cranial irradiation (PCI) in patients with stage-III nonsmall cell lung cancer: exploratory subgroup analyses of the NVALT-11/DLCRG-02 phase-III study.

Witlox WJA, Ramaekers BLT, Groen HJM, Dingemans AM, Praag J, Belderbos J, van der Noort V, van Tinteren H, Joore MA, De Ruysscher DKM.

Acta Oncol. 2019 Jul 1:1-4. doi: 10.1080/0284186X.2019.1629016. [Epub ahead of print] No abstract available.

PMID:
31256737
6.

EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer.

Lindsay CR, Blackhall FH, Carmel A, Fernandez-Gutierrez F, Gazzaniga P, Groen HJM, Hiltermann TJN, Krebs MG, Loges S, López-López R, Muinelo-Romay L, Pantel K, Priest L, Riethdorf S, Rossi E, Terstappen L, Wikman H, Soria JC, Farace F, Renehan A, Dive C, Besse B, Michiels S.

Eur J Cancer. 2019 Aug;117:60-68. doi: 10.1016/j.ejca.2019.04.019. Epub 2019 Jun 27.

7.

The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer.

Degens JHRJ, Sanders KJC, de Jong EEC, Groen HJM, Smit EF, Aerts JG, Schols AMWJ, Dingemans AC.

Lung Cancer. 2019 Jul;133:130-135. doi: 10.1016/j.lungcan.2019.05.021. Epub 2019 May 20.

8.

Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations.

Willemsen AECAB, Krausz S, Ligtenberg MJL, Grünberg K, Groen HJM, Voest EE, Cuppen EPJG, van Laarhoven HWM, van Herpen CML.

Br J Cancer. 2019 Jul;121(1):34-36. doi: 10.1038/s41416-019-0489-3. Epub 2019 May 27.

PMID:
31130724
9.

Methods of computed tomography screening and management of lung cancer in Tianjin: design of a population-based cohort study.

Du Y, Zhao Y, Sidorenkov G, de Bock GH, Cui X, Huang Y, Dorrius MD, Rook M, Groen HJM, Heuvelmans MA, Vliegenthart R, Chen K, Xie X, Liu S, Oudkerk M, Ye Z.

Cancer Biol Med. 2019 Feb;16(1):181-188. doi: 10.20892/j.issn.2095-3941.2018.0237.

10.

Circulating tumor cells are prognostic in SCLC, but still lack clinical application.

Tamminga M, Groen HJM.

Ann Oncol. 2019 Jul 1;30(7):1031-1033. doi: 10.1093/annonc/mdz162. No abstract available.

PMID:
31095269
11.

Air Pollution and Adenocarcinoma in Never-Smokers.

Groen HJM, Hiltermann TJN.

J Thorac Oncol. 2019 May;14(5):761-763. doi: 10.1016/j.jtho.2019.02.007. No abstract available.

PMID:
31027739
12.

Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).

Hermans BCM, Derks JL, Thunnissen E, van Suylen RJ, den Bakker MA, Groen HJM, Smit EF, Damhuis RA, van den Broek EC, Stallinga CM, Roemen GM, Speel EJM, Dingemans AC; PALGA-group.

Lung Cancer. 2019 Apr;130:179-186. doi: 10.1016/j.lungcan.2019.02.022. Epub 2019 Feb 21.

PMID:
30885341
13.

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis.

Holleman MS, van Tinteren H, Groen HJ, Al MJ, Uyl-de Groot CA.

Onco Targets Ther. 2019 Feb 20;12:1413-1421. doi: 10.2147/OTT.S189438. eCollection 2019. Review.

14.

Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients.

de Goeje PL, Poncin M, Bezemer K, Kaijen-Lambers MEH, Groen HJM, Smit EF, Dingemans AC, Kunert A, Hendriks RW, Aerts JGJV.

Clin Cancer Res. 2019 Apr 1;25(7):2219-2227. doi: 10.1158/1078-0432.CCR-18-2243. Epub 2019 Jan 14.

PMID:
30642911
15.

Surgical experience and patient-related restrictions predict the adequacy of cervical mediastinoscopy in non-small cell lung carcinoma lymph node staging.

Klinkenberg TJ, Bouma W, Van De Wauwer C, Wolf RFE, Mariani MA, Groen HJM.

J Cardiothorac Surg. 2018 Dec 29;13(1):134. doi: 10.1186/s13019-018-0821-7.

16.

Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study.

Walter JE, Heuvelmans MA, Ten Haaf K, Vliegenthart R, van der Aalst CM, Yousaf-Khan U, van Ooijen PMA, Nackaerts K, Groen HJM, De Bock GH, de Koning HJ, Oudkerk M.

Thorax. 2019 Mar;74(3):247-253. doi: 10.1136/thoraxjnl-2018-212152. Epub 2018 Dec 27.

PMID:
30591535
17.

Screening for Early Lung Cancer, Chronic Obstructive Pulmonary Disease, and Cardiovascular Disease (the Big-3) Using Low-dose Chest Computed Tomography: Current Evidence and Technical Considerations.

Heuvelmans MA, Vonder M, Rook M, Groen HJM, De Bock GH, Xie X, Ijzerman MJ, Vliegenthart R, Oudkerk M.

J Thorac Imaging. 2019 May;34(3):160-169. doi: 10.1097/RTI.0000000000000379.

PMID:
30550403
18.

Single tube liquid biopsy for advanced non-small cell lung cancer.

de Wit S, Rossi E, Weber S, Tamminga M, Manicone M, Swennenhuis JF, Groothuis-Oudshoorn CGM, Vidotto R, Facchinetti A, Zeune LL, Schuuring E, Zamarchi R, Hiltermann TJN, Speicher MR, Heitzer E, Terstappen LWMM, Groen HJM.

Int J Cancer. 2019 Jun 15;144(12):3127-3137. doi: 10.1002/ijc.32056. Epub 2019 Jan 28.

PMID:
30536653
19.

Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer.

Cramer-van der Welle CM, Peters BJM, Schramel FMNH, Klungel OH, Groen HJM, van de Garde EMW; Santeon NSCLC Study Group; Santeon NSCLC study group.

Eur Respir J. 2018 Dec 20;52(6). pii: 1801100. doi: 10.1183/13993003.01100-2018. Print 2018 Dec.

20.

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.

Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schröder CP, Hiltermann TJN, van der Wekken AJ, Groen HJM, Kwee TC, Elias SG, Gietema JA, Bohorquez SS, de Crespigny A, Williams SP, Mancao C, Brouwers AH, Fine BM, de Vries EGE.

Nat Med. 2018 Dec;24(12):1852-1858. doi: 10.1038/s41591-018-0255-8. Epub 2018 Nov 26.

PMID:
30478423
21.

KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC.

Niemantsverdriet M, Schuuring E, Elst AT, van der Wekken AJ, van Kempen LC, van den Berg A, Groen HJM.

J Thorac Oncol. 2018 Dec;13(12):e249-e251. doi: 10.1016/j.jtho.2018.07.103. No abstract available.

PMID:
30467046
22.

Assessing Lung Cancer Screening Programs under Uncertainty in a Heterogeneous Population.

Broekhuizen H, Groothuis-Oudshoorn CGM, Vliegenthart R, Groen HJM, IJzerman MJ.

Value Health. 2018 Nov;21(11):1269-1277. doi: 10.1016/j.jval.2018.01.021.

PMID:
30442273
23.

Relationship between the number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: The NELSON study.

Walter JE, Heuvelmans MA, de Bock GH, Yousaf-Khan U, Groen HJM, van der Aalst CM, Nackaerts K, van Ooijen PMA, de Koning HJ, Vliegenthart R, Oudkerk M.

Lung Cancer. 2018 Nov;125:103-108. doi: 10.1016/j.lungcan.2018.05.007. Epub 2018 May 14.

24.

Reply to A. Addeo et al, H. Zeng et al, and C.G. Rusthoven.

De Ruysscher DK, Groen HJ.

J Clin Oncol. 2018 Oct 22:JCO1800863. doi: 10.1200/JCO.18.00863. [Epub ahead of print] No abstract available.

PMID:
30346900
25.

A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors.

Atrafi F, Groen HJM, Byers LA, Garralda E, Lolkema MP, Sangha RS, Viteri S, Chae YK, Camidge DR, Gabrail NY, Hu B, Tian T, Nuthalapati S, Hoening E, He L, Komarnitsky P, Calles A.

Clin Cancer Res. 2019 Jan 15;25(2):496-505. doi: 10.1158/1078-0432.CCR-18-2014. Epub 2018 Oct 16.

PMID:
30327308
26.

Classification of Cells in CTC-Enriched Samples by Advanced Image Analysis.

de Wit S, Zeune LL, Hiltermann TJN, Groen HJM, Dalum GV, Terstappen LWMM.

Cancers (Basel). 2018 Oct 10;10(10). pii: E377. doi: 10.3390/cancers10100377.

27.

Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition.

de Boer HR, Pool M, Joosten E, Everts M, Samplonius DF, Helfrich W, Groen HJM, van Cooten S, Fusetti F, Fehrmann RSN, de Vries EGE, van Vugt MATM.

Oncogene. 2019 Feb;38(9):1477-1488. doi: 10.1038/s41388-018-0522-7. Epub 2018 Oct 10.

PMID:
30305724
28.

Respiratory level tracking with visual biofeedback for consistent breath-hold level with potential application in image-guided interventions.

Heerink WJ, Dorrius MD, Groen HJM, Van Ooijen PMA, Vliegenthart R, Oudkerk M.

Eur Radiol Exp. 2018 Sep 5;2:22. doi: 10.1186/s41747-018-0052-7. eCollection 2018 Dec.

29.

Prophylactic cranial irradiation (PCI) in locally advanced non-small cell lung cancer: time for hope?

De Ruysscher DK, Groen HJ.

Oncotarget. 2018 Aug 17;9(64):32274-32275. doi: 10.18632/oncotarget.25866. eCollection 2018 Aug 17. No abstract available.

30.

[An enlarged thymus associated with Graves' disease].

Wouters MPAM, Wolffenbuttel BHR, Links TP, Groen HJM, Wouters RSME.

Ned Tijdschr Geneeskd. 2018 Jul 20;162. pii: D2905. Dutch.

PMID:
30182634
31.

Developing Ultrasensitive Library-Aliquot-Based Droplet Digital PCR for Detecting T790M in Plasma-Circulating Tumor DNA of Non-small-Cell-Lung-Cancer Patients.

Yang K, Li J, Zhao J, Ren P, Wang Z, Wei B, Dong B, Sun R, Wang X, Groen HJM, Ma J, Guo Y.

Anal Chem. 2018 Oct 2;90(19):11203-11209. doi: 10.1021/acs.analchem.8b01776. Epub 2018 Sep 11.

PMID:
30156405
32.

Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?

van der Wekken AJ, Kok K, Groen HJM.

J Thorac Dis. 2018 Jul;10(Suppl 18):S2130-S2132. doi: 10.21037/jtd.2018.06.45. No abstract available.

33.

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification.

Meedendorp AD, Ter Elst A, 't Hart NA, Groen HJM, Schuuring E, van der Wekken AJ.

Front Oncol. 2018 May 22;8:176. doi: 10.3389/fonc.2018.00176. eCollection 2018.

34.

Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study.

De Ruysscher D, Dingemans AC, Praag J, Belderbos J, Tissing-Tan C, Herder J, Haitjema T, Ubbels F, Lagerwaard F, El Sharouni SY, Stigt JA, Smit E, van Tinteren H, van der Noort V, Groen HJM.

J Clin Oncol. 2018 Aug 10;36(23):2366-2377. doi: 10.1200/JCO.2017.77.5817. Epub 2018 May 22.

PMID:
29787357
35.

New Subsolid Pulmonary Nodules in Lung Cancer Screening: The NELSON Trial.

Walter JE, Heuvelmans MA, Yousaf-Khan U, Dorrius MD, Thunnissen E, Schermann A, Groen HJM, van der Aalst CM, Nackaerts K, Vliegenthart R, de Koning HJ, Oudkerk M.

J Thorac Oncol. 2018 Sep;13(9):1410-1414. doi: 10.1016/j.jtho.2018.05.006. Epub 2018 Jul 12.

36.

Characteristics of new solid nodules detected in incidence screening rounds of low-dose CT lung cancer screening: the NELSON study.

Walter JE, Heuvelmans MA, Bock GH, Yousaf-Khan U, Groen HJM, Aalst CMV, Nackaerts K, Ooijen PMAV, Koning HJ, Vliegenthart R, Oudkerk M.

Thorax. 2018 Aug;73(8):741-747. doi: 10.1136/thoraxjnl-2017-211376. Epub 2018 Apr 16.

PMID:
29661918
37.

Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.

Li J, Wang Z, Groen HJM, Zhao J, Wang P, Zhang C, Yang K, Guo Y, Ma J.

Lung Cancer. 2018 Apr;118:173-175. doi: 10.1016/j.lungcan.2018.02.016. Epub 2018 Mar 2. No abstract available.

PMID:
29502892
38.

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers.

Wei J, van der Wekken AJ, Saber A, Terpstra MM, Schuuring E, Timens W, Hiltermann TJN, Groen HJM, van den Berg A, Kok K.

Cancers (Basel). 2018 Jan 4;10(1). pii: E10. doi: 10.3390/cancers10010010.

39.

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

Felip E, Barlesi F, Besse B, Chu Q, Gandhi L, Kim SW, Carcereny E, Sequist LV, Brunsvig P, Chouaid C, Smit EF, Groen HJM, Kim DW, Park K, Avsar E, Szpakowski S, Akimov M, Garon EB.

J Thorac Oncol. 2018 Apr;13(4):576-584. doi: 10.1016/j.jtho.2017.11.131. Epub 2017 Dec 13.

40.

Resource utilization in lung cancer diagnostic procedures: Current use and budget consequences.

Brinkhof S, Groen HJM, Siesling SS, IJzerman MJ.

PLoS One. 2017 Dec 7;12(12):e0189251. doi: 10.1371/journal.pone.0189251. eCollection 2017.

41.

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.

Horn L, Gettinger S, Camidge DR, Smit EF, Janjigian YY, Miller VA, Pao W, Freiwald M, Fan J, Wang B, Chand VK, Groen HJM.

Lung Cancer. 2017 Nov;113:51-58. doi: 10.1016/j.lungcan.2017.08.014. Epub 2017 Aug 31.

42.

Relationship between nodule count and lung cancer probability in baseline CT lung cancer screening: The NELSON study.

Heuvelmans MA, Walter JE, Peters RB, Bock GH, Yousaf-Khan U, Aalst CMV, Groen HJM, Nackaerts K, Ooijen PMV, Koning HJ, Oudkerk M, Vliegenthart R.

Lung Cancer. 2017 Nov;113:45-50. doi: 10.1016/j.lungcan.2017.08.023. Epub 2017 Sep 1.

43.

Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.

Derks JL, Leblay N, Thunnissen E, van Suylen RJ, den Bakker M, Groen HJM, Smit EF, Damhuis R, van den Broek EC, Charbrier A, Foll M, McKay JD, Fernandez-Cuesta L, Speel EM, Dingemans AC; PALGA-Group.

Clin Cancer Res. 2018 Jan 1;24(1):33-42. doi: 10.1158/1078-0432.CCR-17-1921. Epub 2017 Oct 24.

44.

Molecular Tumor Boards: current practice and future needs.

van der Velden DL, van Herpen CML, van Laarhoven HWM, Smit EF, Groen HJM, Willems SM, Nederlof PM, Langenberg MHG, Cuppen E, Sleijfer S, Steeghs N, Voest EE.

Ann Oncol. 2017 Dec 1;28(12):3070-3075. doi: 10.1093/annonc/mdx528.

PMID:
29045504
45.

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.

Soria JC, Adjei AA, Bahleda R, Besse B, Ferte C, Planchard D, Zhou J, Ware J, Morrissey K, Shankar G, Lin W, Schutzman JL, Dy GK, Groen HJM.

Eur J Cancer. 2017 Nov;86:186-196. doi: 10.1016/j.ejca.2017.08.027. Epub 2017 Oct 6.

PMID:
28992562
46.

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE.

Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.

PMID:
28919011
47.

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.

van der Wekken AJ, Kuiper JL, Saber A, Terpstra MM, Wei J, Hiltermann TJN, Thunnissen E, Heideman DAM, Timens W, Schuuring E, Kok K, Smit EF, van den Berg A, Groen HJM.

PLoS One. 2017 Aug 30;12(8):e0182885. doi: 10.1371/journal.pone.0182885. eCollection 2017.

48.

Quality assessment of positron emission tomography scans: recommendations for future multicentre trials.

de Jong EEC, van Elmpt W, Hoekstra OS, Groen HJM, Smit EF, Boellaard R, Lambin P, Dingemans AC.

Acta Oncol. 2017 Nov;56(11):1459-1464. doi: 10.1080/0284186X.2017.1346824. Epub 2017 Aug 22.

PMID:
28830270
49.

Transient thyrotoxicosis during nivolumab treatment.

van Kooten MJ, van den Berg G, Glaudemans AWJM, Hiltermann TJN, Groen HJM, Rutgers A, Links TP.

Neth J Med. 2017 Jun;75(5):204-207.

50.

Quantification of growth patterns of screen-detected lung cancers: The NELSON study.

Heuvelmans MA, Vliegenthart R, de Koning HJ, Groen HJM, van Putten MJAM, Yousaf-Khan U, Weenink C, Nackaerts K, de Jong PA, Oudkerk M.

Lung Cancer. 2017 Jun;108:48-54. doi: 10.1016/j.lungcan.2017.02.021. Epub 2017 Mar 1.

Supplemental Content

Loading ...
Support Center